Indications
Symptomatic treatment of dyspepsia associated with increased acidity of gastric juice and gastroesophageal reflux (heartburn, acid belching), a feeling of heaviness in the stomach after eating, including during pregnancy.
$26.00
Active ingredient: | |
---|---|
Dosage form: | |
Indications for use: | Gastric and duodenal ulcers, Gastritis, Heartburn, Reflux esophagitis |
Symptomatic treatment of dyspepsia associated with increased acidity of gastric juice and gastroesophageal reflux (heartburn, acid belching), a feeling of heaviness in the stomach after eating, including during pregnancy.
Hypersensitivity to any of the components of the drug; phenylketonuria; children under 12 years of age.
With caution:If you have the following diseases or conditions, you should consult your doctor before using the drug: hypercalcemia, nephrocalcinosis and urolithiasis with the formation of calcium-oxalate stones, congestive heart failure, impaired renal function.
Active ingredients:
sodium alginate 250 mg,
sodium bicarbonate 133.5 mg,
calcium carbonate 80 mg;
Excipients:
mannitol 255 mg,
macrogol 20000 30 mg,
magnesium stearate 4 mg,
aspartame 3.75 mg,
copovidone 28 mg,
acesulfame potassium 3.75 mg,
mint flavor 12 mg.
Gaviscon®, chewable tablets [mint]. When taken orally, Gaviscon ® forms a protective barrier on the surface of the stomach contents, preventing acid from flowing from the stomach to the esophagus for up to four hours. A reduction in irritation is felt 3-4 minutes after ingestion. The mechanism of action of the active substances of Gaviscon® is physical and does not depend on absorption into the systemic circulation.
Active ingredients: sodium alginate 250 mg, sodium bicarbonate 133.5 mg, calcium carbonate 80 mg; Excipients: mannitol 255 mg, macrogol 20000 30 mg, magnesium stearate 4 mg, aspartame 3.75 mg, copovidone 28 mg, acesulfame potassium 3.75 mg, mint flavor 12 mg
Gaviscon® enters the stomach and interacts with its contents, forming a protective barrier (raft) that prevents the occurrence of heartburn.
Symptomatic treatment of dyspepsia associated with increased acidity of gastric juice and gastroesophageal reflux (heartburn, acid belching), a feeling of heaviness in the stomach after eating, including during pregnancy.
Hypersensitivity to any of the components of the drug; phenylketonuria; children under 12 years of age. With caution: If you have the following diseases or conditions, you should consult your doctor before using the drug: hypercalcemia, nephrocalcinosis and urolithiasis with the formation of calcium-oxalate stones, congestive heart failure, impaired renal function.
Possible allergic reactions (urticaria, bronchospasm, anaphylactic reactions).
Since calcium carbonate, which is part of the drug, shows antacid activity, then between takingGaviscon® and other medications should take at least 2 hours (especially when taken simultaneously with H2-histamine receptor blockers, tetracycline antibiotics, digoxin, fluoroquinolone, iron salts, ketoconazole, neuroleptics, thyroxine, penicillamine, beta-blockers, glucocorticosteroids, chloroquine and diphosphates).
Inside, after careful chewing. Adults and children over 12 years of age: 2-4 tablets after meals and before bedtime (up to 4 times a day). If symptoms persist after 7 days of taking the drug, you should consult a doctor to review the therapy.
Symptoms: Â Bloating may occur.
Treatment: Â symptomatic.
Gaviscon®, chewable tablets [mint]. When taken orally, Gaviscon ® forms a protective barrier on the surface of the stomach contents, preventing acid from flowing from the stomach to the esophagus for up to four hours. A reduction in irritation is felt 3-4 minutes after ingestion. The mechanism of action of the active substances of Gaviscon® is physical and does not depend on absorption into the systemic circulation.
In a dose of four tablets, the sodium content is 246 mg (10.6 mmol). This should be taken into account if you need to follow a diet with a very limited salt content, for example, in some cases of congestive heart failure and kidney function disorders.
Each dose of four tablets contains 320 mg (3.2 mmol) of calcium carbonate. Caution should be exercised when treating patients with hypercalcemia, nephrocalciposis, and recurrent formation of calcium-containing kidney stones. Due to the content of aspartame in the composition, this drug should not be prescribed to patients with phenylketonuria.
There is a possibility of reducing the effectiveness of the drug in patients with very low levels of gastric acid. If the symptoms do not disappear after seven days of treatment, the clinical condition should be re-evaluated.
Effect on the ability to drive mechanisms and a car
The drug does not affect the ability to drive vehicles and mechanisms, as well as to engage in other potentially dangerous activities that require increased concentration of attention and speed of pisichomotor reactions.
Round, flat tablets with beveled edges, from almost white to cream color with small inclusions, with a mint smell.
On one side of the tablet: the image of a circle and a sword, on the other side: G 250.
At a temperature not exceeding 30 °C. Keep out of reach of children.
Sodium Alginate, Sodium Bicarbonate, Calcium Carbonate
tablets for resorption
Children over 12 years of age, For pregnant women, For adults, Nursing mothers
Heartburn, Gastritis, Reflux Esophagitis, Gastric Ulcer and Duodenal ulcer
Reviews
There are no reviews yet